1. Scrip

Roche Goes Big On KRAS-Mutated Cancers In Hookipa Pact

 
• By Alaric DeArment

Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.

Roche signed a deal with Hookipa worth $25m up front and up to $930m in milestones • Source: Shutterstock

Who: Hookipa Pharma/Roche

What: Roche will receive a license for Hookipa’s HB-700 for KRAS-mutated cancers as well as a second undisclosed novel immunotherapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business